TF2B
TF2B has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Oct 27, 2026: “Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on TF2B
At a glance
The findings reach worms or flies, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Guangdong Provincial Department of Science and Technology
- Model organisms1
What did studies of TF2B find?
2Studies of TF2B measured 2 outcomes: insulin/IGF-1 signaling and lifespan.
Insulin/IGF-1 signaling
downin worms1
1 study
Insulin/IGF-1 signaling
downin worms1
TF2B inhibits insulin/IGF-1 signaling in worms.
“Mechanistically, TF1 and TF2B suppressed the DAF-2-mediated insulin/IGF-1 signaling pathway.”
Model organisms
Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway
Journal of Functional Foods
Lifespan
upin worms1
1 study
Lifespan
upin worms1
TF2B extends lifespan in worms.
“100 μM TF1 and 500 μM TF2B markedly increased lifespan”
Model organisms500 μM
Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway
Journal of Functional Foods